Matt Panuwat is the vice president, business development for Prothena Corporation plc. Matt has over 15 years of experience in the biotechnology industry spanning research, finance and strategic advisory. He has been involved with executing numerous creative collaborations and transformational M&A transactions, both as a principal and advisor.
Matt joined Prothena in 2017 and is responsible for business development and alliance management activities. Prior to Prothena, Matt was the Head of Business Development at Medivation for several years until its acquisition by Pfizer. Prior to Medivation, Matt worked in Corporate Strategic Development at Questcor until its merger with Mallinckrodt plc. Prior to Questcor, Matt spent almost a decade in investment banking at Merrill Lynch focused on M&A and financings for biotechnology companies. Matt started his biotechnology career as an initial employee and research scientist at XenoPort.
Matt holds a BS in Biology from Santa Clara University, MS in Physiology & Biophysics from Georgetown University and MBA from University of California, Los Angeles.